You are definitely undervaluing Neurotrope if you think the world's potentially first treatment for not only Alzheimer's, but several other neurological disorders is going to be valued 10% as much as one of many other cancer treatments.
As Dr. Alkon has stated many times before, Bryostatin 1 has the potential to shift the paradigm of how we treat all kinds of neurological disorders, including stroke, which in itself is a ridiculously massive potential market.
When you hear the word "synaptogenic", it doesn't just mean that it fixes Alzheimer's, it means that it quite literally repairs the circuitry in your brain.
Like I've said many times before, I don't think most people have any idea what a stupendously big revolution in medicine this has the potential to be.
That might also explain why so few people believe in it. It just seems too good to be true.
Confirmatory trial results should put all doubts to rest though, and after that, who knows where the stock price is going to land.
All I know is that opportunities like these only appear once in a lifetime, and that the low stock price today shouldn't be seen as a bad thing, but rather as an opportunity to load up on as many shares as possible, because you know deep in your heart how much more they will be worth only a few years from now once the world realizes what Dr. Alkon has uncovered through his amazing research.
News 
Market Data 
Discover 
